Pediatrics · LP-016
Cefalexin Powder for oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-016Pediatrics
- Generic identity
- CefalexinPowder for oral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-016
- Generic identity
- Cefalexin
- Presentation
- Powder for oral suspension
- Catalogue strength
- 125 mg/5 mL; 250 mg/5 mL
- Catalogue pack
- Bottle for reconstitution 60 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cefalexin/cephalexin.
- Dosage form: powder for oral suspension.
- Proposed concentrations: 125 mg/5 mL and 250 mg/5 mL.
- General proposed final volume: 60 mL.
Layer 02 · Unresolved product-specific fields
- Exact cefalexin compound/basis and formula/excipients.
- Reconstitution water volume/steps, shaking and measuring-device instructions.
- After-reconstitution storage/discard period.
- Approved indication, age range, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 125 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 60 mL | Reconstitution and after-reconstitution handling require the exact controlled product documentation. |
| B | 250 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 60 mL | Reconstitution and after-reconstitution handling require the exact controlled product documentation. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cefalexin, also spelled cephalexin, is a cephalosporin antibiotic used for selected susceptible bacterial infections. Its role depends on the organism and infection site; it should not be described as universally suitable for respiratory or urinary symptoms. Oral capsules and reconstituted liquid preparations have separate administration requirements. This page explains the ingredient for professional reference and does not establish approved Luang Pharma indications or product interchangeability.
Clinical context and therapeutic role
Treatment decisions consider clinical findings, local susceptibility patterns and whether microbiological investigation is required. Some urinary, skin and respiratory infections may fall within the clinical context of cefalexin, but the diagnosis and local guideline determine its place. A detailed history of antibiotic allergy is important. Kidney function, age and ability to use the selected formulation should be reviewed before a professional chooses the appropriate presentation.
Selected safety context
Hypersensitivity reactions, including anaphylaxis and severe skin reactions, can occur. A previous reaction to a cephalosporin or another beta-lactam antibiotic should be discussed before treatment. Diarrhoea, nausea and abdominal discomfort are possible; severe or bloody diarrhoea during or after treatment needs medical review. Renal impairment may increase exposure. Concomitant medicines, including anticoagulants, require a medication review. Seek urgent help for breathing difficulty, facial swelling or a widespread blistering rash.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This presentation is a powder intended to become an oral suspension after product-specific reconstitution. The stated concentration should be interpreted using the registered label, including the final volume. Water volume, preparation method and excipients require confirmation; another product’s instructions cannot be used as a substitute.
Reconstitution should follow the exact supplied instructions and appropriate pharmacy practice. Record the relevant preparation information and use the correct oral measuring device. Check the authorized storage conditions and period after reconstitution; no universal refrigeration rule or discard interval is assumed.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specifications/formula for each concentration.
Approved label/leaflet with exact reconstitution and handling instructions.
Container/closure and measuring-device specification.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: CephalexinArchived source classification: US National Library of Medicine medicine reference | Source revision recorded: Last revised 15 June 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-016.
Professional enquiries
Request product-specific evidence for LP-016.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.